CareDx, Inc. (CDNA)

CareDx's stock (CDNA) has experienced fluctuations, including a 25% gain in the month leading up to November 29, 2025, but was still down 27% over the preceding year. As of April 9, 2026, the stock price was $16.69. Key events include the Q4 and full-year 2025 financial results, which showed revenue increases but a GAAP net loss. New product launches, such as VANTx and AlloHeme, and advancements in Epic Aura integrations were also noted. The company anticipates a $7.5 million impact to revenue and adjusted EBITDA in its 2026 guidance due to an expected finalized LCD policy mid-year. Insider activity shows more stock sales than purchases in the past three months. Analysts have a consensus "Hold" rating with an average price target of $27.33.

CareDx, Inc. has a seasonality score of -18, suggesting some level of demand seasonality for its products and services.

CareDx, Inc. is a precision medicine company focused on developing and commercializing healthcare solutions for transplant patients. It operates in the Healthcare sector, specifically in the Diagnostics & Research industry, providing testing services, products, and digital solutions throughout the transplant patient journey. The company's major testing services include AlloSure Kidney, AlloMap Heart, AlloSure Heart, AlloSure Lung, AlloHeme, HistoMAP Kidney, VANTx, TruSight HLA, and digital health solutions like Ottr and AlloCare.

CareDx, Inc.'s global headquarters are in Brisbane, California, which serves as the central hub for operations, research and development, and clinical laboratory testing. The company has a European office and laboratory in Stockholm, Sweden, which supports the EMEA market. CareDx operates additional sites globally and employs remote and field-based professionals. The majority of its revenue is generated from the United States.

CareDx's brand reputation has been positively influenced by its focus on innovation and the launch of new diagnostic and digital solutions for transplant patients, such as VANTx and AlloHeme. The launch of AlloSure Heart for Pediatrics, Alisure Plus, and HistoMAP Kidney, along with advancements in Epic Aura integrations, contribute to its reputation as a leader in transplant care. The publication of the third SHORE registry manuscript also enhances its scientific credibility. No significant negative events impacting CareDx's brand reputation were found.

CareDx, Inc.'s ownership is diversified among institutional investors, company insiders, and the public market. As of April 15, 2025, institutional investors held approximately 49.54% of the common stock, while insiders owned about 9.42%. The remaining 41.04% was held by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Bamco Inc /ny/.